Vnitr Lek 2008, 54(10):992-999

Hemophilia

P. Smejkal*, M. Matýšková, M. Penka
Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc.

Hemophilia is the most spread hereditary bleeding disorder with severe bleeding symptoms. Although the number of hemophiliacs is below 0.1‰ in population, the care of these patients consumes a lot of financial expenditures, especially for treatment in appearance of inhibitor. Management of hemophilia is best provided by specialist in a hemophilia treatment centre. However, all physicians can meet the patients with hemophilia in urgent situation or with their chronic problems. The aim of this article is to give an overview of this disease from pathophysiology, clinical manifestation and diagnosis (including prenatal) to treatment. We describe most frequent complications of hemophilia treatment, particularly management of inhibitor.

Keywords: hemophilia; diagnosis; treatment; F VIII inhibitor; immune tolerance; guidelines

Received: May 15, 2008; Accepted: June 14, 2008; Published: October 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Smejkal P, Matýšková M, Penka M. Hemophilia. Vnitr Lek. 2008;54(10):992-999.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. White GC, Rozendal F, Aledort L et al. Definitions in Hemophilia. Tromb Haemost 2001; 85: 560. Go to original source...
    2. Forbes CD, Aledort L, Madhok R. Hemophilia. London: Chapman & Hall 1997.
    3. O'Mahony B. WFH: back to the future. Haemophilia 2004; 10 (Suppl 4): 1-8. Go to original source... Go to PubMed...
    4. O'Shaughnessy D, Makris M, Lillicarp D. Practical Hemostasis and Thrombosis. 1st ed. Blackwell Publishing 2005. Go to original source...
    5. Annual Global Survey. World Federation of Hemophilia 2006. http://www.wfh.org/index.asp?lang=EN.
    6. Matýšková M, Penka M. Hemofilie. Vnitř Lék 1991; 37: 397-403. Go to PubMed...
    7. Matýšková M, Zavřelová J, Hrachovinová I. Hematologie pro zdravotní laboranty. 1. vyd. Brno: IDVPZ; 2. díl.
    8. Bolton-Maggs PHB. Optimal haemophilia care versus the reality. Br J Haematol 2005; 132: 671-682. Go to original source... Go to PubMed...
    9. Lee CA, Berntorp E, Hoots WK. Textbook of Hemophilia. 1st ed. Blackwell Publishing 2005. Go to original source...
    10. Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol 2007; 136: 777-787. Go to original source... Go to PubMed...
    11. Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001; 112: 264-274. Go to original source... Go to PubMed...
    12. Guidelines for the Management of Hemophilia. World Federation of Hemophilia 2005. http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Gudelines_Mng_Hemophilia.pdf
    13. Habart D. Směrnice pro správnou laboratorní praxi při molekulárně genetických vyšetřeních u hemofilie A. http://www.uhkt.cz/nrl/nrl-dna/nrl-dna/std_ha.html
    14. Habart D. Von Willebrandova choroba typu 2N (Normandy). Vnitř Lék 2003; 49: 253-255.
    15. Gringeri A, Mannucci PM. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-619. Go to original source... Go to PubMed...
    16. Hay CRM, Brown S, Collins PW et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors' Organisation. Br J Haematol 2006; 133: 591-605. Go to original source... Go to PubMed...
    17. Habart D. Nové obzory v léčbě hemofilie - rekombinantní a transgenní koncentráty, genová léčba a modifikované koagulační faktory. Čas Lék Čes 2006; 145: 104-111.
    18. Guidelines for dental treatment of patients with inherited bleeding disorders. World Federation of Hemophilia 2006. http://www.wfh.org/2 /d ocs/Publications/Dental_Care/TOH-40_Dental_treatment.pdf.
    19. Hemophilia of Georgia, U.S.A. Protocol for the treatment of haemophilia and von Willebrand Disea se. Haemophilia 2000; 6 (Suppl 1): 84-93. Go to original source...
    20. Kubeš R. Hemofilie: Návrh terapeutického postupu u komplikací postihujících pohybový aparát. Zdravotnické noviny 25. 7. 2002.
    21. Astenmark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia 2006; 12 (Suppl 6): 8-14. Go to original source... Go to PubMed...
    22. Pipe SW, Valentino LA. Optimizing outcomes for patients with severe haemophilia A. Haemophilia 2007; 13 (Suppl 4): 1-16. Go to original source... Go to PubMed...
    23. Hay CRM. Prophylaxis in adults with haemophilia. Haemophilia 2007; 13 (Suppl 2): 10-15. Go to original source... Go to PubMed...
    24. Astenmark J, Morado M, Rocino A et al. Current European practise in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-371. Go to original source... Go to PubMed...
    25. Peerlinck K, Jacquemin M. Characteristics of inhibitors in mild/moderate haemophilia A. Haemophilia 2006; 12 (Suppl 6): 43-47. Go to original source... Go to PubMed...
    26. Astenmark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12 (Suppl 3): 52-60. Go to original source... Go to PubMed...
    27. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophila A. Blood 2006; 107: 46-51. Go to original source... Go to PubMed...
    28. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654. Go to original source... Go to PubMed...
    29. Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006; 12: 579-590. Go to original source... Go to PubMed...
    30. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12 (Suppl 6): 54-61. Go to original source... Go to PubMed...
    31. Kenet G, Lubetsky A, Luboshitz J et al. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®). J Thromb Haemost 2003; 1: 450-455. Go to original source... Go to PubMed...
    32. Kavakli K, Makris M, Zulfikar B et al. Home treatment of haemarthroses using a single dose regiment of recombinant activated factor VII in patients with haemophilia and inhibitors. Thromb Haemost 2006; 95: 600-605. Go to original source... Go to PubMed...
    33. Santagostino E, Mancuso ME, Rocino A et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-371. Go to original source... Go to PubMed...
    34. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625-631. Go to original source... Go to PubMed...
    35. Astenmark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-551. Go to original source... Go to PubMed...
    36. Schneiderman J, Rubin E, Nugent DJ et al. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-248. Go to original source... Go to PubMed...
    37. Juvonen E, Kolho E, Anttila VJ et al. Acute myocardial infarction complicating therapy with FVIII followed by APCC and rFVIIa in a 23-year-old man with haemophilia A and FVIII inhibitor. Haemophilia 1998; 4: 240.
    38. Lentz SR. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002; 87: 925-926. Go to original source... Go to PubMed...
    39. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia with inhibitors: a systematic review. Haemophilia 2003; 9: 436-463. Go to original source... Go to PubMed...
    40. DiMichele DM. Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12 (Suppl 6): 81-86. Go to original source... Go to PubMed...
    41. DiMichele DM, Hoots WK, Pipe SW et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl 1): 1-22. Go to original source... Go to PubMed...
    42. Hay CRM, Recht M, Carcao M et al. Current and Future Approaches to Inhibitor Management and Aversion. Semin Tromb Hemost 2006; 32 (Suppl 2): 15-21. Go to original source... Go to PubMed...
    43. Neme D, Candela M, Bianco RP. Rituximab for the management of alloimmune antibodies in a patient with severe haemophilia A and a giant pseudotumor. Haemophilia 2006; 12 (Suppl 2): 57.
    44. Franchini M. Hepatitis C in haemophiliacs. Tromb Haemost 2004; 92: 1259-1268. Go to original source... Go to PubMed...
    45. Husa P, Smejkal P, Husová L et al. Úspěšnost léčby chronické hepatitidy C u hemofiliků v závislosti na historickém vývoji doporučovaných léčebných schémat. Vnitř Lék 2004; 50: 30-35. Go to PubMed...
    46. Makris M, Baglin T, Dusheiko G et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001; 7: 339-345. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.